Indivior divests interest in Suboxone® in China to Pukang

Torreya advised Indivior on this transaction

Slough, UK and Richmond, VA, February 4, 2019

Indivior PLC (LON: INDV), a global specialty pharmaceutical company, signed a definitive agreement to divest its interest in Suboxone® or Sai Bo Song™ tablet in China to Zhejiang Pukang Biotechnology Co., Ltd. (“Pukang”) for a total consideration of up to $122.5 million.

The transaction allows Indivior to streamline the business and focus its resources on the highest return opportunities in the regions they know best. Pukang is a private company focused on biologics and vaccines that is seeking to diversify into small molecule therapies.

Torreya served as financial advisor to Indivior. This transaction reinforces Torreya’s strength and leadership position as an advisor in the China market with five transactions involving a Chinese party announced in the past seven months. Torreya has advised on 32 transactions in the healthcare industry since the beginning of 2018.

ABOUT INDIVIOR PLC:
For more information about Indivior, please see: www.indivior.com

Deal Press Release